Zimmer Biomet (ZBH) Expected to Announce Quarterly Earnings on Thursday

Zimmer Biomet (NYSE:ZBH) will likely be posting its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect Zimmer Biomet to post earnings of $2.30 per share and revenue of $2.01 billion for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Zimmer Biomet Stock Down 0.4 %

Zimmer Biomet stock opened at $107.77 on Wednesday. Zimmer Biomet has a 12-month low of $100.67 and a 12-month high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $21.45 billion, a PE ratio of 20.49, a PEG ratio of 1.88 and a beta of 1.02. The firm’s fifty day moving average is $107.88 and its 200 day moving average is $108.22.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ZBH shares. Raymond James dropped their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Stifel Nicolaus lifted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Truist Financial increased their price target on Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Finally, Wells Fargo & Company lifted their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.